Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs TJX Companies Inc (TJX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs TJX Companies Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $302.38 (market cap $39.89B), while TJX Companies Inc trades at $151.56 (market cap $167.19B). The key difference: TJX Companies Inc is far larger — about 4.2× Alnylam Pharmaceuticals, Inc.'s market cap, and TJX Companies Inc pays a 1.27% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | TJX | |
|---|---|---|
Market Cap | $39.89B | $167.19B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $168.41 |
52-Week Low | $278.09 | $121.35 |
Enterprise Value | $38.15B | $175.79B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
TJX trades at $151.34, showing modest daily gains amid a bearish technical signal. The company demonstrates strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.19 versus $1.02 expected, and robust profitability metrics like a 61.25% ROE. Revenue growth is steady, climbing from $48.5B in 2022 to $56.4B in 2025, with further expansion projected. Recent news highlights TJX's resilience as a blue-chip retailer during market volatility, though technical indicators suggest near-term pressure.
The outlook for TJX remains positive based on fundamental strength and analyst optimism, with a consensus price target of $181.80 implying significant upside. Key opportunities include international expansion and same-store sales growth. Risks involve competitive retail pressures and macroeconomic sensitivity. Wall Street sentiment is overwhelmingly bullish, with 88% of analysts rating it a Buy, supporting a favorable long-term investment case despite short-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →
